Next Article in Journal
The Heart Club: How Cyanotic Heart Disease Was Reframed
Previous Article in Journal
Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease
Article Menu

Export Article

Open AccessReview
Diseases 2017, 5(4), 21; doi:10.3390/diseases5040021

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina 45110, Greece
*
Author to whom correspondence should be addressed.
Received: 14 September 2017 / Revised: 28 September 2017 / Accepted: 29 September 2017 / Published: 29 September 2017
View Full-Text   |   Download PDF [1234 KB, uploaded 29 September 2017]   |  

Abstract

Cholesteryl ester transfer protein (CETP) inhibitors significantly increase serum high-density lipoprotein cholesterol (HDL) cholesterol levels and decrease low-density lipoprotein cholesterol (LDL) cholesterol concentration. However, three drugs of this class failed to show a decrease of cardiovascular events in high-risk patients. A new CETP inhibitor, anacetrapib, substantially increases HDL cholesterol and apolipoprotein (Apo) AI levels with a profound increase of large HDL2 particles, but also pre-β HDL particles, decreases LDL cholesterol levels mainly due to increased catabolism of LDL particles through LDL receptors, decreases lipoprotein a (Lp(a)) levels owing to a decreased Apo (a) production and, finally, decreases modestly triglyceride (TRG) levels due to increased lipolysis and increased receptor-mediated catabolism of TRG-rich particles. Interestingly, anacetrapib may be associated with a beneficial effect on carbohydrate homeostasis. Furthermore, the Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial showed that anacetrapib administration on top of statin treatment significantly reduces cardiovascular events in patients with atherosclerotic vascular disease without any significant increase of adverse events despite its long half-life. Thus, anacetrapib could be useful for the effective management of dyslipidemias in high-risk patients that do not attain their LDL cholesterol target or are statin intolerable, while its role in patients with increased Lp(a) levels remains to be established. View Full-Text
Keywords: anacetrapib; cholesteryl ester transfer protein; cardiovascular disease; apolipoprotein; diabetes anacetrapib; cholesteryl ester transfer protein; cardiovascular disease; apolipoprotein; diabetes
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Filippatos, T.D.; Kei, A.; Elisaf, M.S. Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? Diseases 2017, 5, 21.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top